Vascular and metabolic effects of theophylline, dibuturyl cyclic AMP and dibuturyl cyclic GMP in canine subcutaneous adipose tissue in situ.
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000273:Adipose Tissue / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology*; D000242:Cyclic AMP / Q000494:pharmacology; D006152:Cyclic GMP / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D007773:Lactates / Q000378:metabolism; D050356:Lipid Metabolism; D009638:Norepinephrine / Q000494:pharmacology; D010477:Perfusion; D011773:Pyruvates / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D013268:Stimulation, Chemical; D013806:Theophylline / Q000494:pharmacology*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D005230:Fatty Acids, Nonesterified; D007773:Lactates; D011773:Pyruvates; D003994:Bucladesine; D000255:Adenosine Triphosphate; D004492:Edetic Acid; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP; D005947:Glucose; D005990:Glycerol; D009638:Norepinephrine